{"preliminary_commentary":{"by_channel":{"x_thread":54,"youtube":35,"podcast":28,"bluesky_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05198934\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CodeBreak 300","nct_id":"NCT05198934","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=codebreak-300-nct05198934. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CodeBreak300","arms":[{"description":null,"label":"Arm A: Sotorasib 960 mg QD + panitumumab","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Sotorasib 240 mg QD + panitumumab","type":"EXPERIMENTAL"},{"description":"Participants will be administered trifluridine and tipiracil, or regorafenib","label":"Arm C : Investigator's choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-04-14","type":"ACTUAL"},"conditions":["Colorectal Cancer (CRC)"],"enrollment":{"count":160,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sotorasib","otherNames":["AMG 510, Lumakras, Lumykras"],"type":"DRUG"},{"name":"Panitumumab","otherNames":["Vectibix"],"type":"DRUG"},{"name":"Trifluridine and Tipiracil","otherNames":["Lonsurf"],"type":"DRUG"},{"name":"Regorafenib","otherNames":["Stivarga"],"type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Amgen","official_title":"A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR","timeFrame":"From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months"}],"references":[{"citation":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.","pmid":"37870968","type":"BACKGROUND"},{"citation":"Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Tran Q, Cremolini C, Fakih M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. J Clin Oncol. 2025 Jul;43(19):2147-2154. doi: 10.1200/JCO-24-02026. Epub 2025 Apr 11.","pmid":"40215429","type":"BACKGROUND"},{"citation":"Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. Lancet Oncol. 2025 Sep;26(9):1240-1251. doi: 10.1016/S1470-2045(25)00352-3. Epub 2025 Aug 11.","pmid":"40812325","type":"BACKGROUND"},{"citation":"Salvatore L, Fakih M, Kuboki Y, Hong DS, Modest DP, Taieb J, Price TJ, Cremolini C, Majer IM, Rehn M, Chan E, Chen Z, Tran Q, Pietrantonio F. Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2026 Apr 23:S1533-0028(26)00026-5. doi: 10.1016/j.clcc.2026.04.003. Online ahead of print.","pmid":"42173791","type":"BACKGROUND"}],"start_date":{"date":"2022-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","url":"https://clinicaltrials.gov/study/NCT05198934"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/codebreak-300-nct05198934"}